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ABSTRACT 
Bimatoprost (1) and Latanoprost (2) are prostaglandin analogues widely used for glaucoma 
treatment. We have developed a new chemoenzymatic synthesis for 1 and 2, which utilizes a highly 
stereoselective sequence of biotransformations catalyzed by enzymes belonging to a single 
microorganism (the yeast Pichia anomala). The original synthesis, starting from (–)-Corey lactone 
benzoate (3aR,4R,5R,6aS)-3, was modified by replacing three synthetic steps (C=C reduction, 
stereoselective C=O reduction and hydrolysis/deprotection of the benzoate ester) with a one-pot, 
three-enzymes reaction. The overall biotransformation gave good yields and it was highly 
stereoselective; noteworthy, by engineering the reaction medium, C=C reduction could be 
modulated so that unsaturated (3aR,4R,5R,6aS,3’S)-6 or saturated intermediate 
(3aR,4R,5R,6aS,3’R)-7 could be preferentially obtained. 
 
INTRODUCTION 
Bimatoprost (1) and Latanoprost (2) (Scheme 1) are prostaglandin analogues used for controlling 
the progression of glaucoma by reducing intraocular pressure and have become billion-dollar 
drugs.[1,2] The industrial manufacture of Bimatoprost and Latanoprost is mostly based on variants of 
the original strategy developed by Corey,[3-9] although different synthetic strategies have been 
proposed, including a shorter stereocontrolled organocatalytic synthetic procedure recently 
reported.[10] In the conventional route, the key ketoprostaglandin intermediate (3aR,4R,5R,6aS)-4 is 
obtained by Horner-Wadsworth-Emmons (HWE) condensation of (–)-Corey lactone benzoate 
(3aR,4R,5R,6aS)-3 with the suited ketophosphonate. Key intermediate (3aR,4R,5R,6aS)-4 is then 
reduced by chemoselective hydrogenation (i.e. Lithium Selectride at low temperature) to give the 
unsaturated secondary alcohol (3aR,4R,5R,6aS,3’S)-5 that can be used for the synthesis of 
Bimatoprost after hydrolysis to (3aR,4R,5R,6aS,3’S)-6 (also known as Lactondiol B); alternatively, 
(3aR,4R,5R,6aS,3’S)-5 can be reduced at the double bond with Pd/C catalytic hydrogenation and 
hydrolyzed at the ester moiety to give (3aR,4R,5R,6aS,3’R)-7 (also known as Lactondiol L), the 




Scheme 1. Synthetic routes to Bimatoprost and Latanoprost. 
 
The transformations occurring in the overall conversion of (3aR,4R,5R,6aS)-4 into 
(3aR,4R,5R,6aS,3’S)-6 (C=O reduction and ester hydrolysis) or into (3aR,4R,5R,6aS,3’R)-7 (C=O 
and C=C reduction, ester hydrolysis) can be also enzymatically catalyzed (Scheme 1); more 
specifically, enoate reductases catalyze the reduction of C=C conjugated to an electron withdrawing 
group (such as C=O groups),[11] dehydrogenases (carbonyl reductases) catalyze the reduction of 
C=O groups[12] and esterases catalyze the hydrolysis of esters.[13] Microbial reduction of 
(3aR,4R,5R,6aS)-4 into the corresponding alcohol (3aR,4R,5R,6aS,3’S)-5 has been already reported 
using different yeasts, with Kloeckera jensenii ATCC 20110 giving the best yields.[14] 
In this work, we have studied the possibility to set up a one-pot biocatalytic method for the 
stereocontrolled transformation of (3aR,4R,5R,6aS)-4 directly into (3aR,4R,5R,6aS,3’S)-6 
(Lactondiol B) or (3aR,4R,5R,6aS,3’R)-7 (Lactondiol L) by using different yeasts. 
 RESULTS AND DISCUSSIONS 
A screening for the identification of yeasts (see materials and methods for the complete list) able to 
transform (3aR,4R,5R,6aS)-4 into (3aR,4R,5R,6aS,3’S)-6 and/or (3aR,4R,5R,6aS,3’R)-7 was carried 
out using resting cells suspended in phosphate buffer in the presence of 5% glucose and neat 
(3aR,4R,5R,6aS)-4 (1g/L). Two wild-type strains (Pichia anomala CBS110[15,16] and Pichia 
glucozyma CBS 5766[17-20]) and the recombinant strain Saccharomyces cerevisiae 
BY4741ΔOye2Ks (which has the original OYE2 deleted and bears the highly expressed 
enoatereductase gene from Kazachstania spencerorum)[21] gave molar conversion of 
(3aR,4R,5R,6aS)-4 above 30%. 
Pichia glucozyma CBS 5766 gave ketone (3aR,4R,5R,6aS)-10 (18% yield) and Lactondiol L 
(3aR,4R,5R,6aS,3'S)-7 (69% yield, 72% d.e.) as final products. During the reaction, traces of the 
transient intermediates (3aR,4R,5R,6aS)-8 and (3aR,4R,5R,6aS)-9 were observed, indicating that the 
overall transformation likely occurred as reported in Scheme 2. The reduction of the carbonyl was 
partially enantioselective, furnishing (3aR,4R,5R,6aS,3'S)-7 with 72% d.e. 
 
 
Scheme 2. Biotransformation of 4 with Pichia glucozyma. 
 
Saccharomyces cerevisiae BY4741ΔOye2Ks showed, as expected, high enoate reductase activity 
giving the saturated ketone (3aR,4R,5R,6aS)-8 as the main product (78%) and minor amounts of 10, 
deriving from subsequent ester hydrolysis (Scheme 3). 
 
Scheme 3. Biotransformation of 4 with Saccharomyces cerevisiae BY4741ΔOye2Ks. 
 
Pichia anomala CBS 110 gave a mixture of Lactondiol B (3aR,4R,5R,6aS,3’S)-6 (44% yield, 95% 
d.e.) and Lactondiol L (3aR,4R,5R,6aS,3’R)-7 (30% yield, 97% d.e.), the useful epimers for 
Bimatoprost and Latanoprost synthesis, respectively. Scheme 4 shows the biotransformations 
involved in the conversion of (3aR,4R,5R,6aS)-4 with P. anomala, based on the different 
intermediates observed during the overall transformation. 
 
 
Scheme 4. Biotransformation of 4 with Pichia anomala 
 
It is known that the use of whole cells of yeasts generally gives a mixture of saturated and 
unsaturated alcohols in the reduction of α,β-unsaturated carbonyls, depending on the strain and 
conditions employed;[22] this is due to the relative rates of enoatereductase and carbonyl reductase 
activities, which determine the final ratio of the products. A crucial role in the activity of the 
different reductases can be played by the type of co-substrates added for favouring the regeneration 
of the co-factors involved in the reductions. Thus, the biotransformation with P. anomala was 
carried out using various conventional co-substrates (glucose, ethanol, glycerol, xylose) showing 
the predominant formation of Lactondiol B (3aR,4R,5R,6aS,3’S)-6 with d.e. in the range of 95-97%; 
the use of glucose or glycerol allowed for the highest conversion (44-62%) and diastereoselectivity 
(d.e. 95-97%). The use of fumaric acid gave higher amounts of Lactondiol L (3aR,4R,5R,6aS,3’R)-
7; fumaric acid is an unconventional co-substrate for cofactor regeneration and it is assumed that 
the yeast like Pichia anomala may oxidize fumaric acid in Krebs cycle, therefore allowing for 
regeneration of NAD(P)H. The amount of fumaric acid was varied to check its influence on the 
overall conversion of (3aR,4R,5R,6aS)-4 by whole cells of Pichia anomala and it was observed that, 
when a 5/1 molar ratio of fumaric acid/substrate was employed, (3aR,4R,5R,6aS,3’R)-7 was 
produced in high yields (82%) with only traces of (3aR,4R,5R,6aS,3’S)-6 in the final reaction 
mixture after 7 days. Table 1 summarizes the results obtained using different co-substrates. 
 
   6 7 
entry co-substrate concentration of co-substrate 
g/L 
yield (%) d.e. 
(%) * 
yield (%) d.e. 
(%)* 
1 Ethanol  5 5 n.d. 12 92 
2 Ethanol 50 10 97 20 92 
3 Fumaric acid 5 8 n.d. 75 97 
4 Fumaric acid 50 13 97 70 97 
5 Glucose 5 38 95 25 97 
6 Glucose 50 44 95 30 97 
7 Glycerol 5 57 97 29 97 
8 Glycerol 50 62 97 30 97 
9 Xylose 5 - n.d. 21 96 
10 Xylose 50 - n.d. 33 95 
Table 1 
*determined by HPLC analysis 
 
The biotransformation of (3aR,4R,5R,6aS)-4 catalyzed by Pichia anomala was optimized using the 
Multimplex® experimental design, which simultaneously evaluates different parameters of the 
biotransformation and had previously shown to be suited for the fast optimization of different 
biotransformations.[23,24] The response parameters were product yields and d.e., while the control 
variables were temperature, pH, concentration of cells, concentration of DMSO and co-substrate. 
The best performance for the preparation of (3aR,4R,5R,6aS,3’R)-7 (82% yield, 97% d.e., 7 days) 
was obtained using 0.1 mM phosphate buffer at pH 7.0, 28 °C, 1 g/L substrate concentration in the 
presence of 1.5 g/L fumaric acid, while the best conditions for the preparation of 
(3aR,4R,5R,6aS,3’S)-6 (62% yield, 97% d.e., 7 days) were found using 0.1 mM phosphate buffer at 
pH 7.2, 28 °C, 1 g/L substrate concentration in the presence of 50 g/L glycerol. When the 
biotransformation carried out in the presence of glycerol was stopped after 3 days, a significant 
amount (34%) of the intermediate (3aR,4R,5R,6aS)-9 could be recovered.   
 
CONCLUSIONS 
In conclusion, here we propose an alternative chemoenzymatic approach for the synthesis of 
Bimatoprost and Latanoprost, based on the biotransformation of 15-ketoprostaglandin 
(3aR,4R,5R,6aS)-4 with whole cells of non-conventional yeast Pichia anomala. This appears like a 
useful method for preparing optically pure Lactondiol B (3aR,4R,5R,6aS,3’S)-6 (62%) and 
Lactondiol L (3aR,4R,5R,6aS,3’R)-7. The use of Pichia anomala allows to obtain Lactondiol B 
(3aR,4R,5R,6aS,3’S)-6 or Lactondiol L (3aR,4R,5R,6aS,3’R)-7, depending on the co-substrate 
employed: Lactondiol B (3aR,4R,5R,6aS,3’S)-6 was obtained with 44-62% yield using glucose or 
glycerol, whereas the use of fumaric acid gave 82% yield of Lactondiol L (3aR,4R,5R,6aS,3’R)-8 in 
a simple one-pot, three-step modification of substrate (3aR,4R,5R,6aS)-4. The stereoselectivity of 
the carbonyl reduction depends on the yeast employed, as shown in the case of Pichia glucozyma, 




General experimental information 
All reagents and solvents were obtained from commercial suppliers and were used without further 
purification. Merck Silica Gel 60 F254 plates were used for analytical TLC; 1H and 13C NMR spectra 
were recorded on a Varian-Gemini 200 spectrometer. Flash column chromatography was performed 
on Merck Silica Gel (200-400 mesh). 1H and 13C chemical shifts are expressed in d (ppm) and 
coupling constants (J) in Hertz (Hz). MS analyses were performed on a Varian 320-MS triple 
quadrupole mass spectrometer equipped with an electron spray ionization (ESI) source.  
 
General procedures for microbial screening of transformation of 4 
Eighteen yeasts were used in the primary screening for LB enone (4) modification; the strains were 
chosen among 12 yeasts known for esterase and/or ketoreductase activity (Candida boidini 
CBS6056, Kluyveromyces lactis CBS2359, Kluyveromyces marxianus CBS1553, Kluyveromyces 
marxianus var. lactis CL69 Pichia anomala CBS110, Pichia etchellsii MIM, Pichia glucozyma 
CBS 5766, Saccharomyces cerevisiae CBS1782, Saccharomyces cerevisiae CBS3093, 
Saccharomyces cerevisiae CBS3081, Saccharomyces cerevisiae NCYC 73, Saccharomyces 
cerevisiae Zeus)11 and 6 strains with ketoreductase and/or enoate reductases activity 
(Saccharomyces cerevisiae BY4741, Saccharomyces cerevisiae BY4741ΔOye1, Saccharomyces 
cerevisiae BY4741ΔOye2, Saccharomyces cerevisiae BY4741ΔOye2Cc, Saccharomyces cerevisiae 
BY4741ΔOye2Ks, Saccharomyces cerevisiae L12).[16,17,21] 
Strains from official collections or from our collection (Microbiologia Industriale Milano) were 
routinely maintained on M5YE slants (Barley malt flour 100 g/L (Diagermal), 5 g/L yeast extract 
(Difco), agar 15 g/L, pH 5.6). To obtain cells for biotransformations, the microorganisms were 
cultured in 2 L Erlenmeyer flasks containing 300 mL of M5YE liquid medium (Barley malt flour 
100 g/L (Diagermal), 5 g/L yeast extract (Difco), distilled water pH 5.6), incubated for 48 h at 
28 °C on a reciprocal shaker (150spm). Fresh cells from submerged cultures were centrifuged (5000 
rpm, 20 min) and washed with 0.1 M phosphate buffer, pH 7.0, prior to use. 
Biotransformations were carried out in 10 mL screw-capped test tubes with a reaction volume of 3 
mL with cells (20 g/L, dry weight) suspended in 0.1 M phosphate buffer, pH 7, containing 5% of 
glucose and 1 g/L of (3aR,4R,5R,6aS)-4, at 28 °C under magnetic stirring (500 rpm). 
 
Analyticals 
The biotransformations were monitored by HPLC. Samples (0.5 mL) were taken at regular 
intervals, centrifuged and the aqueous phase was extracted with an equal volume of ethyl acetate; 
substrate and product concentrations were determined by HPLC using a Purospher Star 
RP18e250*4.6 mm (5 µm) (Merck, Darmstadt, Germany), UV detection at 220 nm with a Merck-
Hitachi 655-22 detector and CH3CN/H2O/MeOH (18/72/10) as eluent with a flow rate of 0.8 
mL/min.  
The retention times of substrates and products were: (3aR,4R,5R,6aS)-4 = 29.0 min; 
(3aR,4R,5R,6aS)-5 = 37.8 min; (3aR,4R,5R,6aS)-6 = 58.2 min; (3aR,4R,5R,6aS)-7 = 61.6 min; 
(3aR,4R,5R,6aS)-8 = 22.7 min; (3aR,4R,5R,6aS)-9 = 69.8 min; (3aR,4R,5R,6aS)-10 = 76.7 min. 
The stereochemical composition of 6 was determined by HPLC using a Pinnacle II silica 250*4.6 
mm (4 µm, Restek, Bellefonte, Pennsylvania, U.S.), UV detection at 220 nm with a Merck-Hitachi 
655-22 detector and n-heptane/iPrOH (90/10) as eluent with a flow rate of 1.5 mL/min. The 
retention times of the two epimers were: (3aR,4R,5R,6aS,3'S)-6 = 21.7 min; (3aR,4R,5R,6aS,3'R)-6 
= 25.9 min. 
The stereochemical composition of 7 was determined by HPLC using a Phenomenex Lux 
Cellulose-1 column 250*4.6 mm (5 µm) (Phenomenex, Torrance, California, U.S), UV detection at 
220 nm with a Merck-Hitachi 655-22 detector and cyclohexane/iPrOH (85/15) as eluent with a flow 
rate of 1.0 mL/min. The retention times of the two epimers were: (3aR,4R,5R,6aS,3’R)-7 = 16.4 
min; (3aR,4R,5R,6aS,3’S)-7 = 26.6 min. 




Optimization studies were carried out with Pichia anomala CBS 110. The desired amount of cells 
was suspended in different 0.1 M phosphate buffers containing co-substrates and neat substrate was 
added to reach the desired concentration; the suspensions obtained were shaken (reciprocal shaker, 
150spm) at different temperatures. Samples of 100 µL were withdrawn from the reaction mixture, 
centrifuged, extracted with EtOAc (100 µL) and analysed by HPLC.  
 
[(3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)hexahydro-2H-
cyclopenta[b]furan-2-one] (Lactondiol B, (3S)-6) 
Pichia anomala CBS 110 was grown in a 3.0 L fermenter with 1.5 L of M5YE liquid medium for 
48 h, 28 °C and agitation speed 150 rpm. Fresh cells from submerged cultures were centrifuged and 
washed with 0.1 M phosphate buffer, pH 7.0, resuspended in 0.5 L of phosphate buffer to reach 25 
gdry cells/L concentration of cells and used for biotransformations. Reactions were carried out in 2 L 
Erlenmeyer flask by adding glycerol (25 g) and (3aR,4R,5R,6aS)-4 (500 mg) dissolved in 1% of 
DMSO and keeping the reaction mixture under reciprocal shaking (150 spm) at 28 °C. After 7 days, 
the biotransformation mixture was centrifuged, and the aqueous supernatant was extracted twice 
with EtOAc (350 mL); the organic extract was dried over Na2SO4 and the solvent was evaporated to 
give a crude mixture and the single products were purified by flash chromatography (gradient 7:3; 
5:5; 2:8 n-hexane/EtOAc), furnishing (3aR,4R,5R,6aS,3'S)-6 (232 mg, 62%). 
Colourless oil. Rf= 0.085 (n-hexane/EtOAc 4:6); [a]24D= –5.2 (c = 1.00 CH3CN);  
1H-NMR (CDCl3, 200 MHz):  δ 1.78-1.98 (m, 2H), 2.23-2.36 (m, 1H), 2.44-2.78 (m, 7H), 3.91 (q, J 
= 7.70, 1H, CH2CHOHCH2 ), 4.07 (q, J = 6.97, 1H, CHOH), 4.83-4.92 (m, 1 H, CHOC=O), 5.44 
(dd, J 1= 8.06, J2 = 15.40, 1H, Csp2-H), 5.62 (dd, J1= 6.60, J2= 15.40, 1H, Csp2-H), 7.16-7.29 (m, 
5H, Csp2-H). 
13C-NMR (CDCl3, 50.4 MHz): δ 177.06 (C=O), 141.79 (Csp2quat.), 136.65, 130.51 (Csp2-H), 128.68, 
128.63, 126.20 (Csp2-H), 82.69 (OCHCH2), 76.74 (CHOH), 72.17 (CH2CHOHCH2), 56.39 
(CH2CHCHCHOH), 42.69 (CH2CHCHCHOH), 40.05, 38.89, 34.38, 31.95 (CH2). 
MS (ESI + m/z %): 325.3 [M++Na+] (100). 
 
 [(3aR,4R,5R,6aS)-5-hydroxy-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-
cyclopenta[b]furan-2-one)] (Lactondiol L, (3R)-7) 
Pichia anomala CBS 110 was grown in a 3.0 L fermenter with 1.5 L of M5YE liquid medium for 
48 h, 28 °C and agitation speed 150 rpm. Fresh cells from submerged cultures were centrifuged and 
washed with 0.1 M phosphate buffer, pH 7.0, resuspended in 0.5 L of phosphate buffer to reach 25 
gdry cells/L of cells and used for biotransformations. Reactions were carried out in 2 L Erlenmeyer 
flask by adding fumaric acid (719 mg) and (3aR,4R,5R,6aS)-4 (500 mg) dissolved in 1% of DMSO 
and keeping the reaction mixture under reciprocal shaking (150 spm) at 28 °C. After 7 days, the 
biotransformation mixture was centrifuged, and the aqueous supernatant was extracted twice with 
EtOAc (350 mL); the organic extract was dried over Na2SO4 and the solvent evaporated to give a 
crude mixture and the products were purified by flash chromatography (gradient 7:3; 5:5; 2:8 n-
hexane/EtOAc), furnishing (3aR,4R,5R,6aS,3’R)-7 (308 mg, 82%). 
Colourless oil. Rf= 0.087 (n-hexane/EtOAc 4:6); [α]24D= –25.0 (c = 2.00 CH3CN);  
1H-NMR (CDCl3, 200 MHz): δ 1.22-1.28 (m, 1H), 1.46-1.59 (m, 3H), 1.73-1.81 (m, 3H), 2.21-2.28 
(m, 1H), 2.43-2.50 (m, 2H), 2.64-2.80 (m, 2H), 3.60-3.66 (m, 1H, CH2CHOHCH2), 3.97 (q, J = 5.1 
1H, CHOH), 4.88-4.96 (m, 1 H, CHOC=O), 7.16-7.27 (m, 5H, Csp2-H). 
13C-NMR(CDCl3, 50.4 MHz): δ 177.95 (C=O), 142.13 (Csp2quat.), 128.68, 128.62, 126.15 (CHsp2), 
84.20 (OCHCH2), 77.65 (CHOH), 71.52 (CH2CHOHCH2), 54.16 (CH2CHCHCHOH), 43.43 
(CH2CHCHCHOH), 40.69, 39.31, 36.22, 35.43, 32.26, 29.18 (CH2). 
MS (ESI + m/z %): 327.3 [M++Na+] (100). 
 
 [(3aR,4R,5R,6aS)-5-hydroxy-4-((S)-3-hydroxy-5-phenylpentyl)hexahydro-2H-
cyclopenta[b]furan-2-one] (Lactondiol L, (3S)-7) 
Pichia glucozyma CBS 5766 was grown in a 3.0 L fermenter with 1.5 L of M5YE liquid medium 
for 48 h, 28°C and agitation speed 150 rpm. Fresh cells from submerged cultures were centrifuged 
and washed with 0.1 M phosphate buffer, pH 7.0, resuspended in 0.5 L of phosphate buffer to reach 
25 gdry cells/L concentration of cells and used for biotransformations. Reactions were carried out in 2 
L Erlenmeyer flask by adding glycerol (25 g) and (3aR,4R,5R,6aS)-4 (500 mg) dissolved in 1% of 
DMSO and keeping the reaction mixture under reciprocal shaking (150 spm) at 28°C. After 7 days, 
the biotransformation mixture was centrifuged, and the aqueous supernatant was extracted twice 
with EtOAc (350 mL); the organic extract was dried over Na2SO4 and the solvent was evaporated to 
give a crude mixture and the single products were purified by flash chromatography (gradient 7:3; 
1:1; 2:8 n-hexane/EtOAc), furnishing (3aR,4R,5R,6aS,3’S)-7 (260 mg, 69%). 
Colourless oil. Rf= 0.087 (n-hexane/EtOAc 4:6); [α]24D= + 18.9 (c = 2.00 CH3CN).  
 [(3aR,4R,5R,6aS)-5-hydroxy-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-
cyclopenta[b]furan-2-one] (9). 
Compound (3aR,4R,5R,6aS)-9 was obtained starting from intermediate (3aR,4R,5R,6aS)-4, 
following the same procedure described for the synthesis of compound (3aR,4R,5R,6aS3’R)-7 and 
stopping the reaction after 3 days. The reaction mixture was purified by flash chromatography 
(gradient 7:3; 1:1; 2:8 n-hexane/EtOAc), furnishing (3aR,4R,5R,6aS)-9 (126 mg, 34%). 
Brown oil. Rf= 0.28 (n-hexane/EtOAc 4:6); 
1H-NMR (CDCl3, 200 MHz): δ 1.50-1.85 (m, 2H), 2.20-2.30 (m, 1H), 2.30-2.50 (m, 3H), 2.58-2.72 
(m, 2H), 2.90-3.0 (m, 2H), 4.10 (q, J = 6.90 1H, CHOH), 4.83-4.92 (m, 1 H, CHOC=O), 6,20 (d, J 
= 15.30, 1H,Csp2-H), 6.60 (dd, J1 = 6.23, J2 = 15.33, 1H, Csp2-H), 7.15-7.30 (m, 5H, Csp2-H). 
 
 [(3aR,4R,5R,6aS)-2-oxo-4-(3-oxo-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-5-yl 
benzoate] (8) and [(3aR,4R,5R,6aS)-5-hydroxy-4-(3-oxo-5-phenylpentyl)hexahydro-2H-
cyclopenta[b]furan-2-one] (10).  
 
Saccharomyces cerevisiae BY4741ΔOye2Ks was grown in a 3.0 L fermenter with 1.5 L of M5YE 
liquid medium for 48 h, 28°C and agitation speed 150 rpm. Fresh cells from submerged cultures 
were centrifuged and washed with 0.1 M phosphate buffer, pH 7.0, resuspended in 0.5 L of 
phosphate buffer to reach 20 gdry cells/L concentration of cells and used for biotransformations. 
Reactions were carried out in 2 L Erlenmeyer flask by adding glucose (50 g) and (3aR,4R,5R,6aS)-4 
(500 mg) dissolved in 1% of DMSO and keeping the reaction mixture under reciprocal shaking 
(150 spm) at 28°C. After 7 days, the biotransformation mixture was centrifuged, and the aqueous 
supernatant was extracted twice with EtOAc (350 mL); the organic extract was dried over Na2SO4 
and the solvent was evaporated to give a crude mixture and the single products were purified by 
flash chromatography (gradient 7:3; 1:1; 2:8 n-hexane/EtOAc), furnishing 392 mg of 
(3aR,4R,5R,6aS)-8 (392 mg, 78%) and (3aR,4R,5R,6aS)-10 (30 mg, 8%). 
(3aR,4R,5R,6aS)-8: White solid. Rf= 0.55 (n-hexane/EtOAc 4:6); 
1H-NMR  (CDCl3, 200 MHz): δ 1.58-1.79 (m, 2H), 2.00-2.20 (m, 1H), 2.40-2.60 (m, 3H), 2.62-2.80 
(m, 3H), 2.82-2.98 (m, 5H), 5.05-5.12 (m, 1H, CHOC=O), 5.14-5.20 (m, 1H, PhOCOCH), 7.10-
7.32 (m, 5H, Csp2-H), 7.40-7.50 (m, 2H, Csp2-H), 7.52-7.60 (m, 1H, Csp2-H), 8.10 (d, J = 6.98, 2H, 
Csp2-H).   
(3aR,4R,5R,6aS)-10: Colourless oil. Rf= 0.25 (n-hexane/EtOAc 4:6); 
1H-NMR (CDCl3, 200 MHz): δ 1.40-1.50 (m, 1H), 1.55-1.72 (m, 3H), 1.95-2.10 (m, 2H), 2.30-2.55 
(m, 4H), 2.70-2.82 (m, 2H), 2.87-2.98 (m, 2H), 3.82 (q, J= 5.6, 1H, CHOH), 4.79-4.86 (m, 1H, 
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